Predictive value of peripheral blood CCL5 combined with CXCL14 for survival outcomes in patients with hepatitis B virus-related decompensated cirrhosis complicated by liver failure
摘要
目的 探讨外周血C-C基序趋化因子配体5(CCL5)联合C-X-C基序趋化因子配体14(CXCL14)对乙型肝炎肝硬化失代偿期(HBV-DC)并发肝衰竭(LF)患者生存结局的预测价值.方法 本研究为前瞻性研究,选取2022年1月至2024年12月南京市浦口人民医院消化内科收治的HBV-DC并发LF患者106例(LF组),根据肝硬化分期分为3期组(37例)、4期组(41例)、5期组(28例),按照1∶1比例选取同期收治的单纯HBV-DC患者106例(非LF组)作为对照.采用酶联免疫吸附法检测外周血CCL5、CXCL14水平,比较不同肝硬化分期HBV-DC并发LF患者外周血CCL5、CXCL14水平.根据90 d生存结局分为死亡组和存活组,通过多因素logistic回归分析HBV-DC并发LF患者生存结局的影响因素;通过受试者工作特征(ROC)曲线分析外周血CCL5联合CXCL14对HBV-DC并发LF患者生存结局的预测价值.结果 LF组外周血 CCL5、CXCL14 水平为 9.39(6.48,13.47)ng/mL、6.28(3.99,9.98)ng/mL,高于非 LF 组的 4.62(3.66,5.51)ng/mL、3.23(2.41,3.98)ng/mL,差异有统计学意义(均 P<0.001).3 期组、4 期组、5 期组外周血 CCL5[5.83(3.34,10.13)ng/mL、9.20(7.29,13.42)ng/mL、13.49(9.32,15.83)ng/mL]、CXCL14[4.31(1.92,6.85)ng/mL、6.55(3.94,9.66)ng/mL、10.60(7.53,13.95)ng/mL]水平依次升高(均 P<0.001).106 例 HBV-DC 并发 LF 患者 90 d 死亡率为38.68%(41/106).与存活组比较,肝硬化5期[48.78%比12.31%]、肝性脑病比例(26.83%比9.23%)、脓毒症比例(24.39%比4.62%)、消化道静脉曲张出血比例(70.73%比 41.54%)、MELD 评分[(28.85±6.89 分)比(21.95±4.93分)]增加,CCL5[13.63(9.85,15.50)ng/mL 比 7.31(4.38,9.98)ng/mL]、CXCL14[10.03(6.80,12.03)ng/mL 比 4.91(2.31,7.41)ng/mL]水平升高(均 P<0.05).脓毒症[OR(95%CI):5.985(1.951~18.354),P=0.002]、消化道静脉曲张出血[OR(95%CI):4.346(1.283~14.720),P=0.018]、MELD 评分[OR(95%CI):1.357(1.108~1.663),P=0.003]、CCL5[OR(95%CI):1.934(1.353~2.764),P<0.001]、CXCL14[OR(95%CI):1.962(1.367~2.814),P<0.001]为HBV-DC并发LF患者死亡的独立危险因素.外周血CCL5、CXCL14水平及二者联合预测HBV-DC并发LF患者生存结局的曲线下面积为0.844、0.833、0.936,二者联合优于各自单独预测效能(Z=2.909、3.024,P=0.004、0.003).结论 外周血CCL5、CXCL14水平升高与HBV-DC并发LF患者肝硬化加重及生存结局不良密切相关,二者联合预测生存结局的价值进一步提升.
Objective This study aimed to investigate the predictive value of peripheral blood C-C motif chemokine ligand 5(CCL5)combined with C-X-C motif chemokine ligand 14(CXCL14)for survival outcomes in patients with hepatitis B virus-related decompensated cirrhosis(HBV-DC)complicated by liver failure(LF).Methods This prospective study included 106 patients with HBV-DC and LF(LF group)admitted to the Department of Gastroenterology of Nanjing Pukou People's Hospital between January 2022 and December 2024.According to cirrhosis staging,they were divided into the stage-3 group(n=37),the stage-4 group(n=41),and the stage-5 group(n=28).An additional 106 patients with HBV-DC without LF,1∶1-matched for admission time,were selected as the non-LF group.An enzyme-linked immunosorbent assay(ELISA)was used to measure peripheral blood levels of CCL5 and CXCL14.Levels of CCL5 and CXCL14 were compared across different cirrhosis stages in the LF group.Based on 90-day survival outcomes,patients were divided into the survival and the death groups.Multivariate logistic regression analysis was performed to identify factors influencing prognosis.Receiver operating characteristic(ROC)curve analysis was conducted to assess the predictive value of CCL5 and CXCL14,alone and in combination,for 90-day survival outcomes.Results Peripheral blood levels of CCL5 and CXCL14 in the LF group[9.39(6.48,13.47)ng/mL and 6.28(3.99,9.98)ng/mL]were significantly higher than those in the non-LF group[4.62(3.66,5.51)ng/mL and 3.23(2.41,3.98)ng/mL](all P<0.001).CCL5 and CXCL14 levels increased progressively with cirrhosis severity across stages 3,4 and 5(all P<0.001).The 90-day mortality rate among HBV-DC patients with LF was 38.68%(41/106).Compared with the survival group,the death group had higher proportions of stage-5 cirrhosis(48.78%vs.12.31%),hepatic encephalopathy(26.83%vs.9.23%),sepsis(24.39%vs.4.62%),gastrointestinal variceal bleeding(70.73%vs.41.54%)and higher MELD scores(28.85±6.89 vs.21.95±4.93),as well as elevated levels of CCL5[13.63(9.85,15.50)ng/mL vs.7.31(4.38,9.98)ng/mL]and CXCL14[10.03(6.80,12.03)ng/mL vs.4.91(2.31,7.41)ng/mL](all P<0.05).Multivariate analysis identified sepsis[OR(95%CI):5.985(1.951~18.354),P=0.002],gastrointestinal variceal bleeding[OR(95%CI):4.346(1.283~14.720),P=0.018],MELD score[OR(95%CI):1.357(1.108~1.663),P=0.003],CCL5[OR(95%CI):1.934(1.353~2.764),P<0.001]and CXCL14[OR(95%CI):1.962(1.367~2.814),P<0.001]as independent risk factors for death.The area under the ROC curve(AUC)for CCL5,CXCL14,and their combination in predicting survival was 0.844,0.833,and 0.936,respectively;the combined model outperformed either marker alone(Z=2.909 and 3.024,P=0.004 and 0.003,respectively).Conclusion Elevated peripheral blood levels of CCL5 and CXCL14 are closely associated with worsening cirrhosis and poor survival outcomes in patients with HBV-DC complicated by LF.The combination of CCL5 and CXCL14 enhances the predictive value for survival outcomes.